Summary
The enzymatic conversion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine to 1-methyl-4-phenylpyridinium ion by monoamine oxidase-B is an essential step mediating the dopaminergic neurotoxicity. Since monoamine oxidase-B is located primarily in serotonergic neurons and astrocytes, the production of 1-methyl-4-phenylpyridinium ion is thought to be extra-dopaminergic. This study provides evidence in support of this conclusion. Pretreating mice with fluoxetine (a serotonergic uptake inhibitor) before the administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine attenuated the dopaminergic neurotoxicity. This was not the result of a nonspecific inhibition of dopaminergic uptake, as fluoxetine pretreatment did not attenuate the dopaminergic neurotoxicity resulting from the intrastriatal administration of the 1-methyl-4-phenylpyridinium ion. Further localization of the primary site of 1-methyl-4-phenylpyridinium ion production as being astrocytes was provided by the failure of 5,7-dihydroxytryptamine-induced serotonergic lesions to attenuate the neurotoxicity produced by administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, whereas, fluoxetine pretreatment in similarly lesioned subjects, continued to attenuate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity. These results are consistent with the hypothesis that astrocytes are a principle site of 1-methyl-4-phenylpyridinium ion production.
Similar content being viewed by others
References
Baumgarten HG, Jenner S, Klemm HP (1981) Serotonin neurotoxins: recent advances in the mode of administration and molecular mechanism of action. J Physiol (Paris) 77: 309–314
Bjorklund A, Baumgarten GG, Nobin (1974) Chemical lesioning of central monoamine axons by means of 5,6-dihydroxytryptamine and 5,7-dihydroxytryptamine. In: Costa E, Gessa GL, Sandler M (eds) Advances in biochemical psychopharmacology, vol 10. Raven Press, New York, pp 13–33
Bradbury AJ, Costall B, Jenner PG, Kelly ME, Marsden CD, Naylor RJ (1985) The neurotoxic actions of 1-methyl-4-phenylpyridine (MPP+) are not prevented by deprenyl treatment. Neurosci Lett 58: 177–181
Brooks WJ, Jarvis MF, Wagner GC (1986) Mediation of MPTP-induced dopaminergic neurotoxicity by serotonergic neurons. Society for Neuroscience, Washington, D.C. (poster)
Burns RS, Chiueh CC, Markey SP, Ebert HM, Jacobowitz DM, Kopin IJ (1983) A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by n-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 80: 4546–4550
Chiba K, Trevor AJ, Castagnoli N (1984) Metabolism of the neurotoxic tertiary amine MPTP by brain monoamine oxidase. Biochem Biophys Res Commun 120: 574–578
Davis GC, Williams AC, Markey SP, Ebert MH, Reichert CM, Kopin IJ (1979) Parkinsonism secondary to intravenous injection of meperidine analogues. Psychiatry Res 1: 249–254
Fibiger HC, Miller JJ (1977) An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 2: 975–987
Fuller RW, Perry KW, Molloy BB (1975) Effect of 3-(p-trifluromethylphenoxy)methyl-3-phenylpropylamine on the depletion of brain serotonin by 4-chloroamphetamine. J Pharmacol Exp Ther 193: 796–803
Heikkila RE, Hess A, Duvoisin RC (1984a) Dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridiine in mice. Science 244: 1451–1453
Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984b) Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469
Jarvis MF, Wagner GC (1985) Age dependent effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Neuropharmacology 24: 581–582
Javitch JA, Snyder SH (1984) Uptake of MPP+ by dopamine neurons explains selectivity of parkinsonian inducing toxin, MPTP. Eur J Pharmacol 106: 455–456
Kimelberg HK (1986) Occurrence and functional significance of serotonin and catecholamine uptake by astrocytes. Biochem Pharmacol 35: 2273–2281
Kimelberg HK, Katz DM (1985) High-affinity uptake of serotonin into immunocytochemically identified astrocytes. Science 228: 889–891
Langston JW, Ballard P, Tetrud JW, Irwin I (1983) Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219: 979–980
Langston JW, Forno LS, Rebert CS, Irwin I (1984a) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the squirrel monkey. Brain Res 292: 390–394
Langston JW, Irwin I, Langston EB, Forno LS (1984b) Pargyline prevents MPTP induced parkinsonism in primates. Science 225: 1480–1482
Levitt P, Pintar JE, Breakfield XO (1982) Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci USA 79: 6385–6389
Mayer RA, Jarvis MF, Wagner GC (1985) Cocaine blocks the neurotoxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine(MPTP). Res Commun Chem Pathol Pharmacol 49: 145–148
Ricaurte GA, Langston JA, Delanney LE, Irwin I, Brooks JD (1985) Dopamine uptake blockers protect against the dopamine depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the mouse striatum. Neurosci Lett 59: 259–264
Shen RS, Abell CW, Gessner W, Brassi A (1985) Serotonergic conversion of MPTP and dopaminergic accumulation of MPP+. FEBS 189: 225–230
Steinbusch HWM, Nieuwenhuys R, Verhofstad AAJ, Van der Kooy D (1981) The nucleus raphe dorsalis of the rat and its projection upon the caudatoputamen. A combined cytoarchitectonic, immunohistochemical and retrograde transport study. J Physiol (Paris) 77: 157–174
Sundstrom E, Jonsson G (1986) Differential time course protection by monoamine oxidase inhibition an uptake inhibition against MPTP neurotoxicity on central catecholamine neurons in mice. Eur J Pharmacol 122: 275–278
Wagner GC, Gardner J, Tsigas DJ, Masters DB (1984) Tolerance following the repeated administration of high doses of phencyclidine: No relation to central catecholamine depletion. Drug Alcohol Depend 13: 225–234
Westlund KN, Denney LM, Kochersperger RM, Abell (1985) Distinct monoamine oxidase A and B populations in primate brain. Science 230: 181–183
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Brooks, W.J., Jarvis, M.F. & Wagner, G.C. Astrocytes as a primary locus for the conversion MPTP into MPP+ . J. Neural Transmission 76, 1–12 (1989). https://doi.org/10.1007/BF01244987
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01244987